Dr. Ian Flinn, MD
Claim this profileSarah Cannon Research Institute
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
17 reported clinical trials
23 drugs studied
About Ian Flinn, MD
Education:
- Earned an MD (Doctor of Medicine).
- Completed a PhD in Clinical Investigations.
Experience:
- Served as the Director of Blood Cancer Research at Sarah Cannon Research Institute.
- Authored over 240 scientific manuscripts.
- Held a leadership role in clinical research at the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Appointed as Associate Professor of Oncology at Johns Hopkins.
- Recently became the Chief Scientific Officer at OneOncology and Tennessee Oncology.
Area of expertise
1Lymphoma
Global LeaderStage I
Stage II
Stage IV
2Non-Hodgkin's Lymphoma
MYC positive
BCL2 positive
BCL6 positive
Affiliated Hospitals
Clinical Trials Ian Flinn, MD is currently running
CAR T-Cell Therapy + Ibrutinib
for Chronic Lymphocytic Leukemia
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
Recruiting1 award Phase 1 & 212 criteria
CAR T-Cell Therapy
for Non-Hodgkin's Lymphoma
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.
Recruiting1 award Phase 1 & 2
More about Ian Flinn, MD
Clinical Trial Related5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Ian Flinn, MD has experience with
- Brentuximab Vedotin
- Nivolumab
- CD30.CAR-T
- Rituximab
- CLBR001
- Doxorubicin
Breakdown of trials Ian Flinn, MD has run
Lymphoma
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ian Flinn, MD specialize in?
Ian Flinn, MD focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage II.
Is Ian Flinn, MD currently recruiting for clinical trials?
Yes, Ian Flinn, MD is currently recruiting for 7 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Ian Flinn, MD has studied deeply?
Yes, Ian Flinn, MD has studied treatments such as Brentuximab Vedotin, Nivolumab, CD30.CAR-T.
What is the best way to schedule an appointment with Ian Flinn, MD?
Apply for one of the trials that Ian Flinn, MD is conducting.
What is the office address of Ian Flinn, MD?
The office of Ian Flinn, MD is located at: Sarah Cannon Research Institute, Nashville, Tennessee 37203 United States. This is the address for their practice at the Sarah Cannon Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.